Umecrine Cognition AB Sustainability Reports
Umecrine Cognition AB is a pharmaceutical development company focused on creating novel therapies for neurological and neuroinflammatory disorders. Its lead clinical drug candidate, golexanolone, is designed to treat cognitive impairment and central fatigue caused by altered GABA signaling.
Sector: Manufacturing
Country: Sweden
Exchange: Unlisted
LEI: 894500AF89I6QWOX2Q84
5 reports from 2021 to 2023
Company Profile
Umecrine Cognition AB is a pharmaceutical development company focused on creating novel therapies for neurological and neuroinflammatory disorders. Its lead clinical drug candidate, golexanolone, is designed to treat cognitive impairment and central fatigue caused by altered GABA signaling.
Reports
5 total
Limited sustainability disclosure available
The reports currently shown are annual reports without dedicated sustainability sections.
